Astria Therapeutics Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. In Phase 1 clinical trials in adults, CAT-1004 inhibited activated NF-kB and was well tolerated with no observed safety concerns.” (Page 75) Read the full document
Astria Therapeutics, Inc., formerly Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is in preclinical development for the treatment of hereditary angioedema (HAE).
Company Website: https://astriatx.com